Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling

BACKGROUND: Tumor-treating fields (TTFields) have been extensively used to treat various cancers as well as glioblastoma multiforme (GBM), owing to their antimitotic effects. Furthermore, sorafenib is also extensively used to treat hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Ho, Lee, Won Seok, Oh, Hoon-Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459640/
https://www.ncbi.nlm.nih.gov/pubmed/36093532
http://dx.doi.org/10.21037/tcr-21-1853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459640/
https://www.ncbi.nlm.nih.gov/pubmed/36093532
http://dx.doi.org/10.21037/tcr-21-1853

Ejemplares similares